# Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.

> **NCT04219241** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Azidus Brasil** · enrollment: 35 (estimated)

## Conditions studied

- Huntington Disease

## Interventions

- **BIOLOGICAL:** Cellavita-HD

## Key facts

- **NCT ID:** NCT04219241
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-10
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04219241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04219241, "Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04219241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*